Two protein-protein interaction networks relevant to immunotherapy were also observed for genes upregulated in blood cancers (Fig 8): one included the recurrent cancer antigens such as GAGE1, MAGEC2 and SSX1, whereas the other network mainly included products of interleukin-related genes involved in malignancy progression such as IL1, IL17, IL19, IL22 and IL23. The gene discussed is IL17A; the disease is hematopoietic and lymphoid system neoplasm.